Pre-eclampsia: Pathophysiology, diagnosis, and management

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 467-474

  Uzan, Jennifer ^a   Carbonnel, Marie ^a   Piconne, Olivier ^a,c   Asmar, Roland ^b   Ayoubi, Jean Marc ^a  

^a FOCH HOSPITAL   (France)

^b University Hospital Foundation for Medical Researches   (Switzerland)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Epidemiology; Pathophysiology; Pre eclampsia; Therapeutic management

Indexed keywords

BLOOD PRESSURE; DELIVERY; FEMALE; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

BLOOD PRESSURE; DELIVERY, OBSTETRIC; FEMALE; HUMANS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84856374300     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s20181     Document Type: Review

References (49)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365: 785-799.
2. Pottecher T, Luton D. Prise en Charge Multidisciplinaire de la Prééclampsie. Issy Les Moulineaux, France: Elsevier Masson SAS; 2009. French.
3. Carty DM, Delles C, Dominiczak AF. Preeclampsia and future maternal health. J Hypertens. 2010;28:1349-1355.
4. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-137.
5. Zhang J, Zeisler J, Hatch MC, Berkowitz G. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev. 1997;19:218-232.
6. Barton JR, Sibai BM. Prediction and prevention of preeclampsia. Obstet Gynecol. 2008;112(2 Pt 1):359-372.
7. Rijhsinghani A, Yankowitz J, Strauss AR, et al. Risk of preeclampsia in second-trimester triploid pregnancies. Obstet Gynecol. 1997;90: 884-888.
8. Julian CG. High altitude during pregnancy. Clin Chest Med. 2011;32: 21-31.
9. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12:1-270.
10. Osmond C, Kajantie E, Forsén TJ, Eriksson JG, Barker DJ. Infant growth and stroke in adult life: the Helsinki Birth Cohort Study. Stroke. 2007;38:264-270.
11. Eriksson JG, Forsén T, Tuomilheto J, Osmond C, Barker DJ. Early growth and coronary heart disease in later life: longitudinal study. BMJ. 2001;322:949-953.
12. Barker DJ, Martyn CN, Osmond C, Hales CN, Fall CH. Growth in utero and serum cholesterol concentrations in adult life. BMJ. 1993; 307:1524-1527.
13. Fisher SJ, McMaster M, Roberts M. The placenta in normal pregnancy and preeclampsia. In: Chesley's Hypertensive Disorders in Pregnancy. Amsterdam, the Netherlands: Academic Press, Elsevier; 2009.
14. Duran-Reyes G, Gomes-Melendez MR, Morali De La Brena G, Mrecado-Pichardo E, Medina-Navarro R, Hicks-Gomez JJ. Nitric oxide synthesis inhibition suppresses implantation and decreases CGMP concentration and protein peroxidation. Life Sci. 1999;65:2259-2268.
15. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol. 1998;16:5-15.
16. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med. 2008;36:38-58.
17. Genbacev O, Difederico E, McMaster M, Fisher SJ. Invasive cytotrophoblast apoptosis in pre-eclampsia. Hum Reprod. 1999;14:59-66.
18. Colbern GT, Chiang MH, Main EK. Expression of the nonclassic histocompatibility antigen HLA-G by preeclamptic placenta. Am J Obstet Gynecol. 1994;170:1244-1250.
19. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 2004;111:200-206.
20. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res. 2011;127(Suppl 3):S72-S75.
21. [No authors listed]. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;133:S1-S22.
22. Multidisciplinary management of severe pre-eclampsia (PE). Experts' guidelines 2008. Société française d'anesthésie et de réanimation. Collège national des gynécologues et obstétriciens français. Société française de médecine périnatale. Société française de néonatalogie. Ann Fr Anesth Reanim. 2009;28:275-281.
23. Haddad B, Kayem G, Deis S, Sibai BM. Are perinatal and maternal outcomes different during expectant management of severe preeclampsia in the presence of intrauterine growth restriction? Am J Obstet Gynecol. 2007;196:237. e1-e5.
24. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979-988.
25. Haddad B, Sibai BM. Expectant management in pregnancies with severe pre eclampsia. Semin Perinatol. 2009;33:143-151.
26. Haddad B, Deis S, Goffinet F, Paniel BJ, Cabrol D, Sibai BM. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 2004;190:1590-1595.
27. Jenkins SM, Head BB, Hauth JC. Severe preeclampsia at,25 weeks of gestation: maternal and neonatal outcomes. Am J Obstet Gynecol. 2002;186:790-795.
28. Budden A, Wilkinson L, Buksh MJ, McCowan L. Pregnancy outcome in women presenting with pre-eclampsia at less than 25 weeks gestation. Aust N Z J Obstet Gynaecol. 2006;46:407-412.
29. Duley L, Henderson-Smart J, Meher S. Drugs for treatment of very high blood pressure during pregnacy. Cochrane Database Syst Rev. 2006;(3):CD001449.
30. Olsen KS, Beier-Holgersen R. Fetal death following labetalol administration in pre-eclampsia. Acta Obstet Gynecol Scand. 1992;7:145-147.
31. Amorin MMR, Santos LC, Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe pre eclampsia. Am J Obstet Gynecol. 1999;180:1283-1288.
32. Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009;114:669-673.
33. Sibai BM. Diagnosis, prevention and management of eclampsia. Am Coll Obstet Gynecol. 2005;105:402-410.
34. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357:2002-2006.
35. Funai EF, Friedlander Y, Paltiel O, et al. Long-term mortality after preeclampsia. Epidemiology. 2005;16:206-215.
36. Tan LK, de Swiet M. The management of postpartum hypertension. BJOG. 2002;109:733-736.
37. Mostello D, Catlin TK, Roman L, Holcomb WL Jr, Leet T. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol. 2002;187:425-429.
38. Royal College of Obstetricians and Gynaecologists. Pre-eclampsia-study group consensus statement. Available from: http://www.rcog. org.uk/womens-health/clinical-guidance/pre-eclampsia-study-groupconsensus-statement. Accessed June 8, 2011.
39. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre eclampsia: population based cohort study. BMJ. 2001;323:1213-1217.
40. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol. 2004;104:1367-1391.
41. Gomez O, Martinez JM, Figueras F, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol. 2005;26:490-494.
42. Rizzo G, Capponi A, Cavicchioni O, Vendola M, Arduini D. First trimester uterine Doppler and three-dimensionnal ultrasound placental volume calculation in predicting pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2008;138:147-151.
43. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
44. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326. e1-e13.
45. Thilaganathan, Wormald B, Zanardini C, Sheldon J, Ralph E, Papageorghiou AT. Early-pregnancy multiple serum markers and second-trimester uterine artery Doppler in predicting preeclampsia. Obstet Gynecol. 2010;115:1233-1238.
46. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-1798.
47. Sergio F, Maria Clara D, Gabriella F, et al. Prophylaxis of recurrent preeclampsia: low-molecular-weight heparin plus low-dose aspirin versus low-dose aspirin alone. Hypertens Pregnancy. 2006;25: 115-127.
48. Villar J, Abdel-Aleem H, Merialdi M, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006;194:639-649.
49. Maynard SE, Karumanchi SA, Thadhani R. Hypertension and kidney disease in pregnancy. In: Brenner BM, editor. Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA: WB Saunders; 2007.